

Medistim Capital Markets Day 2024

Next steps and Innovations for Accelerated Growth

Monday, December 16th

8:00-10:30 GMT (9:00-11:30 CET)

Queen Elizabeth II Centre

Broad Sanctuary, Westminster

London, SW1P 3EE

Room: Burton & Redgrave

Register below:

[Register to join online](#)

[Register to attend in person](#)

Next Steps and Innovations for Accelerated Growth

In surgery, every decision counts. Medistim's MiraQ transit time flow measurement (TTFM) and high-frequency ultrasound (HFUS) imaging devices play a critical role in supporting surgeons and their teams in the operating room – where the decisions can mean the difference between life and death for patients.

In the midst of complex Cardiac, Vascular, and Transplant surgeries, Medistim is there to streamline workflows, simplify data interpretation, and enhance the surgical team's confidence, particularly when reassessing a graft is crucial.

We actively listen to their feedback and experiences, and it is our pledge to continually improving our solutions to make their work—and their lives—easier. This commitment drives our dedication to innovation in both product development and clinical research.

At this Capital Markets Day, you'll be introduced to INTUI, our software platform that will be launched on December 13th 2024 at the ICC congress. INTUI is designed to enhance decision-making in coronary artery bypass graft (CABG) surgery. You'll also hear about PATENT, a new clinical study in Peripheral Bypass surgery that has the potential to become a landmark in the use of TTFM and HFUS imaging for treating critical limb-threatening ischemia (CLTI).

You'll have the opportunity to engage with world-renowned experts as they share their experiences and insights on the future of these vital surgical fields.

And finally, you will learn how these initiatives will help drive adoption of Medistim's devices in Cardiac, Vascular and Transplant surgery.

Presenters



John D. Puskas

MD, PhD, Professor of Cardiovascular Surgery, Chief of Cardiothoracic Surgery at Emory University Hospital Midtown in Atlanta, Georgia




Gianluca Torregrossa

MD, Associate Prof, Director of Robotic & Surgical Revascularization Program at Lankenau Heart Institute, Philadelphia



Maarit Venermo

MD, Professor of vascular surgery at Helsinki University Hospital and University of Helsinki



Michael S. Conte

MD, Professor at Division of Vascular and Endovascular Surgery, UCSF University of California, San Francisco



Kari E. Krogstad

President & CEO
Medistim ASA



Anne Waaler

VP Medical
Medistim ASA



Tore Skjeggstad

Product & Business Manager
Medistim ASA

Agenda

- 8:00 - 8:30 **Breakfast & coffee**
- 8:30 - 8:50 **President & CEO Kari E. Krogstad**
Next steps and innovations for accelerated growth
- 8:50 - 9:00 **Product & Business Manager Tore Skjeggstad**
Introducing INTUI - our new software platform – an intuitive solution optimized to provide data interpretation guidance and enhancing surgical decision-making for better patient outcomes
- 9:00 - 9:15 **Prof. John D. Puskas**
A heart surgeon's perspective on the future of coronary revascularization in light of endovascular alternatives, CT-FFR techniques and new medication. Why does INTUI matter?
- 9:15 - 9:30 **Associate Prof. Gianluca Torregrossa**
A perspective on educating the next generation of surgeons - how can INTUI help? My experience as an early access user
- 9:30 - 9:40 **Q&A first session**
- 9:40 - 9:50 **VP Medical, Anne Waaler**
Introduction to PATENT - a new clinical study on the use of TTFM and HFUS in Peripheral Bypass surgery for treating critical limb-threatening ischemia (CLTI) patients
- 9:50 - 10:00 **Prof. Michael S. Conte (Video recording)**
The lead investigator of the PATENT study on its importance and value
- 10:00 - 10:15 **Prof. Maarit Venermo**
Showcasing real-life examples and best practices on the use of TTFM and HFUS in Peripheral Bypass surgery
- 10:15 - 10:20 **Q&A second session**
- 10:20 - 10:30 **President & CEO Kari E. Krogstad**
Q&A and closing remarks

“

Our vision is that blood flow measurements and intra-operative ultrasound imaging shall benefit all patients and surgeons, regardless of where in the world they are located, and that Medistim's device and solution represent standard clinical practice in every country.

- Kari E. Krogstad